PREMIER:

The purpose of this randomized, multi-site, clinical trial is to determine whether intensive therapy consisting of cholesterol-lowering statin drugs plus apheresis to cleanse (filter out) the blood of low-density lipoprotein (LDL) cholesterol is more effective than statin therapy alone in reducing plaque volume in heart arteries of patients who have already suffered an acute coronary syndrome (ACS). The study will also investigate whether this intensive approach can help increase the presence of endothelial progenitor cells (EPC), stem cells that have been shown to reduce cardiovascular events in patients with heart disease. This study has II phases, Phase I has been completed, and FDA approval for phase II has been received. The study is funded by the Department of Veterans Affairs with Dr. Subhash Banerjee as the principal investigator.

Contact: Michelle Lytal,RN at 214-857-0305 Michelle.Lytal@va.gov

XLPAD Registry:

XLPAD is an observational multi-site registry study designed to evaluate the effectiveness and use of stent and non-stent based therapies among patients undergoing minimally invasive (endovascular) treatment of peripheral artery disease (PAD). Approximately 2,174 patients will be enrolled at approximately 20 sites worldwide. The registry has high-level of data verification and core laboratory adjudication of clinical data and procedure data. Patient management and treatment decisions are at the discretion of the care team per routine clinical practice. The study is supported by the University of Texas Southwestern Medical Center though access to RedCap data acquisition system. Dr. Subhash Banerjee is the principal investigator. Please visit www.XLPAD.org for additional information of the study and PAD in general.

Contact: Preeti Kamath at 214-857-3048 Preeti.Kamath@va.gov